# COPD Exacerbation and Long-Term Management

## Pathophysiology and Diagnosis

COPD is characterized by persistent airflow limitation resulting from airway inflammation, small airway remodeling, and parenchymal destruction (emphysema). The underlying pathophysiology involves chronic neutrophilic and CD8+ T-cell inflammation, oxidative stress, protease-antiprotease imbalance, and mucociliary dysfunction. The diagnosis is confirmed spirometrically by a post-bronchodilator FEV1/FVC ratio below 0.70. Severity is graded by the GOLD classification:

| GOLD Stage | Severity | FEV1 (% predicted) |
|-----------|----------|-------------------|
| GOLD 1 | Mild | ≥80% |
| GOLD 2 | Moderate | 50-79% |
| GOLD 3 | Severe | 30-49% |
| GOLD 4 | Very severe | <30% |

### GOLD ABE Assessment (Updated 2023)

The updated GOLD ABE classification replaces the prior ABCD system. It is based on symptom burden (measured by mMRC or CAT score) and exacerbation history. Group A includes patients with low symptoms and low exacerbation risk. Group B includes those with high symptoms but low exacerbation risk. Group E captures any patient who has had an exacerbation requiring hospitalization or two or more moderate exacerbations per year, regardless of symptom level.

## Acute Exacerbation of COPD (AECOPD)

### Definition

An acute exacerbation is defined as acute worsening of dyspnea, cough, and/or sputum production beyond normal day-to-day variation that requires a change in therapy. The most common triggers are viral infections (rhinovirus, influenza, RSV) in 50 to 70 percent of cases, and bacterial infections (H. influenzae, M. catarrhalis, S. pneumoniae, and P. aeruginosa in severe COPD) in 25 to 50 percent. Non-infectious triggers include air pollution, pulmonary embolism, pneumothorax, heart failure, and medication non-adherence.

### Initial Assessment

The initial evaluation focuses on assessing severity and the need for ventilatory support. Key studies include SpO2, ABG (if the exacerbation is severe or NIV is anticipated), chest X-ray, CBC, BMP, and BNP (if heart failure is suspected). An ECG helps rule out arrhythmia, right ventricular strain, and ACS. Sputum cultures are reserved for patients with frequent exacerbations, prior resistant organisms, or ICU-level illness. CT pulmonary angiography should be considered when there is clinical suspicion for PE, which is present in 16 to 25 percent of patients hospitalized for AECOPD.

### Pharmacologic Management of AECOPD

#### Bronchodilators

Short-acting beta-agonists (SABA), typically albuterol at 2.5 mg nebulized or 4 to 8 puffs via MDI with spacer every 1 to 4 hours, are the cornerstone of acute bronchodilator therapy. Nebulized and MDI-with-spacer delivery are equally effective. Ipratropium (SAMA) at 0.5 mg nebulized every 4 to 6 hours is commonly added, though the combination has no clear superiority over SABA alone in the acute setting. Continuous nebulization may be used for severe exacerbations.

#### Systemic Corticosteroids

The REDUCE trial established that 5 days of prednisone 40 mg daily is non-inferior to 14 days, and this has become the standard. IV methylprednisolone is substituted when the patient cannot take oral medications. Corticosteroids produce faster improvement in FEV1, reduce treatment failure, and shorten hospital stays. The most common adverse effect is hyperglycemia, followed by insomnia and, with prolonged use, myopathy.

#### Antibiotics

Antibiotics are indicated when there is increased sputum purulence combined with increased dyspnea and/or sputum volume (Anthonisen criteria), or in any exacerbation requiring mechanical ventilation. First-line options include amoxicillin-clavulanate, azithromycin, or doxycycline for 5 to 7 days. When Pseudomonas risk is present (frequent exacerbations, recent antibiotics, severe COPD, or prior Pseudomonas isolation), a fluoroquinolone or anti-pseudomonal beta-lactam should be used.

#### Oxygen Therapy

Oxygen should be titrated to a target SpO2 of 88 to 92 percent. Excessive supplementation can worsen hypercapnia through the Haldane effect and suppression of hypoxic ventilatory drive. A Venturi mask is preferred for precise FiO2 delivery. ABG should be repeated 30 to 60 minutes after initiation or any change in flow rate.

### Non-Invasive Ventilation (NIV) in AECOPD

NIV has strong evidence for use when there is respiratory acidosis (pH below 7.35, PaCO2 above 45) despite initial bronchodilator therapy. Typical starting settings are IPAP 10 to 15 cmH2O and EPAP 4 to 6 cmH2O, titrated for comfort and gas exchange. NIV reduces intubation rates by approximately 60 percent and reduces both mortality and ICU length of stay. Patients should be reassessed within 1 to 2 hours, and if worsening, intubation should proceed. Contraindications include cardiac or respiratory arrest, hemodynamic instability, inability to protect the airway, and facial trauma.

### Intubation and Mechanical Ventilation

Indications for intubation include NIV failure, respiratory arrest, severe acidosis (pH below 7.20), hemodynamic instability, and altered consciousness. The ventilator strategy must avoid dynamic hyperinflation (auto-PEEP) by using a low respiratory rate (10 to 14 per minute), longer expiratory time (I:E ratio 1:3 to 1:4), and moderate tidal volumes (6 to 8 mL/kg IBW). Extrinsic PEEP should be applied at approximately 80 percent of measured auto-PEEP to reduce the triggering threshold. Permissive hypercapnia is acceptable provided the pH remains above 7.20.

### Discharge Criteria and Planning

Patients should be able to use their inhaler correctly and maintain SpO2 above 88 percent on room air or home oxygen for at least 24 hours. Short-acting bronchodilators should be needed no more frequently than every 4 hours, and the patient should be clinically stable for 12 to 24 hours. Discharge planning includes a 30-day follow-up appointment, inhaler technique review, optimization of chronic therapy, rescue medication, and an exacerbation action plan.

## Chronic (Stable) COPD Management

### Non-Pharmacologic Interventions

Smoking cessation is the single most important intervention to slow FEV1 decline. Patients should be offered pharmacotherapy (varenicline, nicotine replacement, bupropion) along with behavioral support. Pulmonary rehabilitation improves exercise capacity, dyspnea, and quality of life while reducing hospitalizations, and should be offered to all patients with mMRC of 2 or greater or after an exacerbation. Vaccinations should include influenza (annually), pneumococcal (PCV20 or PCV15 plus PPSV23), COVID-19, Tdap, zoster (age 50 and older), and RSV (age 60 and older). Supplemental oxygen is indicated for resting PaO2 of 55 mmHg or less or SpO2 of 88 percent or less (or PaO2 55 to 59 with polycythemia, cor pulmonale, or pulmonary hypertension). The LOTT trial showed no benefit for moderate hypoxemia.

### Pharmacologic Therapy -- Stepwise Approach (GOLD 2024)

| GOLD Group | Criteria | Initial Therapy | Escalation |
|-----------|----------|----------------|-----------|
| A | Low symptoms (mMRC 0-1, CAT <10), 0-1 moderate exacerbations | SABA or SAMA PRN; consider LABA or LAMA | — |
| B | High symptoms (mMRC ≥2, CAT ≥10), 0-1 moderate exacerbations | LABA + LAMA | Evaluate and treat other causes of dyspnea |
| E | ≥2 moderate exacerbations OR ≥1 hospitalization | LABA + LAMA | Eos ≥300: add ICS; Eos <100: add azithromycin or roflumilast |

For Group A patients (low symptoms, low risk), a SABA or SAMA as needed is sufficient, with consideration of LABA or LAMA monotherapy. Group B patients (high symptoms, low risk) should receive a LABA plus LAMA combination, with escalation from monotherapy if persistent dyspnea continues. Group E patients (exacerbation-prone) should start with LABA plus LAMA. If blood eosinophils are 300 or greater, triple therapy with LABA plus LAMA plus ICS is appropriate. If eosinophils are 100 to 300 and exacerbations continue on LABA plus LAMA, adding ICS should be considered. If eosinophils are below 100, ICS should be avoided, and azithromycin or roflumilast should be considered instead.

### Key Medication Classes

Long-acting beta-agonists include formoterol, salmeterol, indacaterol, olodaterol, and vilanterol. Long-acting muscarinic antagonists include tiotropium, umeclidinium, glycopyrrolate, and aclidinium. Inhaled corticosteroids include fluticasone, budesonide, and beclomethasone. Fixed LABA/LAMA combinations include umeclidinium-vilanterol, tiotropium-olodaterol, and glycopyrrolate-formoterol. Triple therapy with fluticasone furoate-umeclidinium-vilanterol (Trelegy Ellipta) was supported by the IMPACT and ETHOS trials, which demonstrated reduced exacerbations and all-cause mortality compared to LABA/LAMA alone in patients with eosinophils of 150 or greater.

### ICS in COPD -- Who Benefits?

ICS provides benefit to patients with blood eosinophils of 300 or greater, frequent exacerbations (two or more per year or at least one hospitalization), and those with asthma-COPD overlap. Risks include increased pneumonia (demonstrated in the TORCH and INSPIRE trials), oral candidiasis, skin bruising, and adrenal suppression. ICS withdrawal should be considered when eosinophils are below 100, there have been no exacerbations on current therapy, the patient has recurrent pneumonia, or response has been poor.

### Add-on Therapies for Persistent Exacerbations

Daily azithromycin 250 mg reduces exacerbation frequency by approximately 27 percent (Albert et al., NEJM 2011), with risks of hearing loss, QT prolongation, and antibiotic resistance. Roflumilast, a PDE4 inhibitor, is indicated for patients with FEV1 below 50 percent, chronic bronchitis phenotype, and frequent exacerbations, though GI side effects (nausea, diarrhea, weight loss) are common. Dupilumab has recently shown efficacy in reducing exacerbations in COPD patients with eosinophils of 300 or greater (BOREAS and NOTUS trials), representing an emerging biologic option for type 2 COPD.

### Surgical and Interventional Options

Lung volume reduction surgery benefits patients with upper-lobe-predominant emphysema and low exercise capacity (NETT trial). Bronchoscopic lung volume reduction with endobronchial valves is an option for severe hyperinflation with absent collateral ventilation. Lung transplantation is reserved for advanced COPD with progressive decline despite maximal medical therapy.

## Alpha-1 Antitrypsin Deficiency

All COPD patients should be screened at least once for alpha-1 antitrypsin deficiency, as recommended by ATS/ERS. It should be suspected in patients with early-onset COPD (before age 45), basilar emphysema, family history, or liver disease. Diagnosis begins with a serum AAT level, and if low, genotyping confirms the diagnosis (Pi*ZZ being the most severe). Treatment includes IV augmentation therapy for patients with FEV1 25 to 80 percent predicted, and smoking cessation is imperative.

<image>
A stepwise treatment algorithm for stable COPD based on the GOLD 2024 ABE classification. Start with the ABE assessment box showing symptom and exacerbation criteria. Branch into Group A (bronchodilator PRN), Group B (LABA + LAMA), and Group E (LABA + LAMA, with escalation based on blood eosinophil count: >=300 add ICS for triple therapy, <100 add azithromycin or roflumilast). Include a side panel showing eosinophil-guided ICS decision-making thresholds.
</image>

<image>
An infographic comparing the management approach for AECOPD severity levels. Three columns: Mild (outpatient, rescue bronchodilators, short course steroids), Moderate (ED/hospital, nebulized bronchodilators, systemic steroids, antibiotics if purulent sputum), and Severe (ICU, NIV or intubation, IV steroids, broad-spectrum antibiotics). Each column includes key decision points, monitoring parameters, and evidence-based citations (REDUCE trial for steroid duration, NIV evidence).
</image>

<image>
A clinical diagram showing the pathophysiology of dynamic hyperinflation in COPD during mechanical ventilation. Illustrate the pressure-volume loop changes with air trapping, the flow-time waveform showing incomplete expiration with auto-PEEP, and the hemodynamic consequences (decreased venous return, hypotension). Include ventilator management strategies: reduced respiratory rate, increased expiratory time, and application of extrinsic PEEP.
</image>

## Clinical Pearls

Oxygen should be targeted to SpO2 88 to 92 percent in AECOPD, as excessive supplementation can worsen hypercapnia via the Haldane effect and suppression of hypoxic drive. Five days of prednisone 40 mg is just as effective as 14 days (REDUCE trial), and steroids should not be over-prescribed. NIV is the intervention with the strongest mortality benefit in AECOPD with respiratory acidosis and should be initiated early. Blood eosinophils are the key biomarker guiding ICS use in COPD: levels of 300 or greater favor ICS benefit, while levels below 100 suggest minimal benefit with increased pneumonia risk. Triple therapy (LABA/LAMA/ICS) reduces all-cause mortality in patients with eosinophils of 150 or greater and frequent exacerbations, as demonstrated by the IMPACT and ETHOS trials. Alpha-1 antitrypsin levels should be checked at least once in every COPD patient, as it is the most common genetic cause of COPD. PE is found in up to 25 percent of patients hospitalized for AECOPD, so a high index of suspicion should be maintained, especially when the exacerbation does not respond as expected.

## References

- Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2024 Report. www.goldcopd.org.
- Leuppi JD, et al. REDUCE Trial: Short-term vs. Conventional Glucocorticoid Therapy in AECOPD. JAMA. 2013.
- Albert RK, et al. Azithromycin for Prevention of COPD Exacerbations. NEJM. 2011.
- Rabe KF, et al. IMPACT Trial: Triple Therapy in COPD. NEJM. 2020.
- Rabe KF, et al. ETHOS Trial: Triple Therapy in COPD. NEJM. 2020.
- Bhatt SP, et al. BOREAS Trial: Dupilumab in COPD with Type 2 Inflammation. NEJM. 2023.
- Long-Term Oxygen Treatment Trial (LOTT). NEJM. 2016.
- Fishman A, et al. NETT Trial: Lung Volume Reduction Surgery. NEJM. 2003.